A couple studies in the medical literature tend to support the use of fluvoxamine for early treatment of COVID-19. Click the links below for specific results of the research.
Fluvoxamine is available as a generic and is also sold in the the U.S. as brand name Luvox. It is FDA-approved for obsessive-compulsive disorder (OCD). It’s also used off-label for several other psychiatric disorders. The usual starting dose for OCD is 50 mg/day, increasing gradually to 100-300 mg/day if needed. The most common side effects are headache (30% of users), insomnia (30%), drowsiness (25%), nausea (35%), and weakness (20%). It is significantly less well-tolerated than ivermectin.
The Lenze study of fluvoxamine for COVID-19 was published in JAMA Network in November 2020. It used this dosing protocol:
Participants received a dose of 50 mg of fluvoxamine (or matching placebo) in the evening immediately after the baseline assessment and confirmation of eligibility, then for 2 days at a dose of 100 mg twice daily as tolerated, and then increasing to a dose of 100 mg 3 times daily as tolerated through day 15 then stopped. That’s a much more rapid dose escalation than the manufacturer recommends for OCD.
Click for the Seftel study of fluvoxamine if interested. This research was less cleanly-designed compared to Lenze. For instance, a fair number of study subjects didn’t even have symptoms at the time of “diagnosis,” just a positive SARS-CoV-2 antigen test (PCR?). The dose of fluvoxamine was a 50-100 mg loading dose on day 1 followed by 50 mg twice daily for 14 days.
Emergency Use Authorization
All the available U.S. vaccines against COVID-19 are under Emergency Use Authorization. What does this mean? From the FDA:
An Emergency Use Authorization (EUA) is a mechanism to facilitate the availability and use of medical countermeasures, including vaccines, during public health emergencies, such as the current COVID-19 pandemic. Under an EUA, FDA may allow the use of unapproved medical products, or unapproved uses of approved medical products in an emergency to diagnose, treat, or prevent serious or life-threatening diseases or conditions when certain statutory criteria have been met, including that there are no adequate, approved, and available alternatives.
So if there are adequate, approved, and available alternatives to the vaccines, the vaccinations must halt for now. Until they pass the usual multi-year tests that prove adequate safety.
If you think the FDA is immune to pressure from politicians and Big Pharma, think again.
Steve Parker, M.D.